iQIYI, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
iQIYI, Inc. (IQ) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of CNY 37.90 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-03-16
- iQIYI, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-12-31 was 12.89M CNY, a 67.97% decline year-over-year.
- iQIYI, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-12-31 was 40.24M CNY, a 85.20% decline year-over-year.
- iQIYI, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2022-12-31 was 271.87M CNY, a 95.62% increase year-over-year.
- iQIYI, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2021-12-31 was 138.98M CNY.
CNY
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | 37.90M CNY 20-F · filed 2026-03-16 | |||
| 2024-12-31 | 12.89M CNY derived: 20-F 12 month − 6-K 9 month · filed 2026-03-16 | 146.50M CNY 20-F · filed 2026-03-16 | 146.53M CNY 20-F · filed 2025-03-27 | |
| 2024-09-30 | 133.61M CNY 6-K · filed 2025-02-20 | |||
| 2023-12-31 | 40.24M CNY derived: 20-F 12 month − 6-K 9 month · filed 2026-03-16 | 280.60M CNY 20-F · filed 2026-03-16 | 280.61M CNY 20-F · filed 2024-03-14 | |
| 2023-09-30 | 240.36M CNY 6-K · filed 2025-02-20 | |||
| 2022-12-31 | 271.87M CNY derived: 20-F 12 month − 6-K 9 month · filed 2025-03-27 | 458.56M CNY 20-F · filed 2025-03-27 | ||
| 2022-09-30 | 186.69M CNY 6-K · filed 2023-01-17 | |||
| 2021-12-31 | 138.98M CNY derived: 20-F 12 month − 6-K 9 month · filed 2024-03-14 | 168.08M CNY 20-F · filed 2024-03-14 | ||
| 2021-09-30 | 29.10M CNY 6-K · filed 2023-01-17 | |||
| 2020-12-31 | 0.00 CNY derived: 20-F 12 month − 6-K 9 month · filed 2023-03-22 | 73.20M CNY 20-F · filed 2023-03-22 | ||
| 2020-09-30 | 73.20M CNY 6-K · filed 2020-12-15 | |||
| 2019-12-31 | 142.27M CNY derived: 20-F 12 month − 6-K 9 month · filed 2022-03-28 | 169.37M CNY 20-F · filed 2022-03-28 | ||
| 2019-09-30 | 27.10M CNY 6-K · filed 2020-12-15 | |||
| 2018-12-31 | 0.00 CNY 20-F · filed 2021-03-09 |
USD
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|
| 2025-12-31 | $5.40M 20-F · filed 2026-03-16 | ||
| 2024-12-31 | $1.04M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-27 | $20.07M 20-F · filed 2025-03-27 | |
| 2024-09-30 | $19.04M 6-K · filed 2025-02-20 | ||
| 2023-12-31 | $39.52M 20-F · filed 2024-03-14 | ||
| 2022-12-31 | $40.24M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-22 | $66.48M 20-F · filed 2023-03-22 | |
| 2022-09-30 | $26.24M 6-K · filed 2023-01-17 | ||
| 2021-12-31 | $26.38M 20-F · filed 2022-03-28 | ||
| 2020-12-31 | $437.00K derived: 20-F 12 month − 6-K 9 month · filed 2021-03-09 | $11.22M 20-F · filed 2021-03-09 | |
| 2020-09-30 | $10.78M 6-K · filed 2020-12-15 | ||
| 2019-12-31 | $24.33M 20-F · filed 2020-03-12 |